达妥昔单抗β治疗神经母细胞瘤的安全性分析

打开文本图片集

【中图分类号】R969.3【文献标志码】A【收稿日期】2024-05-06

【Abstract】Objective：To analyze the clinical characteristics of adverse reactions caused by dinutuximab β for the treatment of neuroblastoma（NB）in China and to provide safety evidence for the rational use of dinutuximab β inclinical practice.Methods：Clinical data wereretrospectivelycollected from16 pediatric patients withNBwho had been treated with dinutuximab β at Shanghai Children' sMedicalCenterAfiliatedtoShanghaiJiaoTong UniversityScholofMedicinefromJanuaryO2 toNovember2O23，ndtheadverse reactions caused by dinutuximab β were summarized and analyzed.Results：The male-to-female ratio was 5：3among the 16 children with NB.The retroperitoneum was the main initial site of involvement，accounting for 75% .Thirteen（ 81.25% ）patients had high-risk NB.The adverse reactions caused by dinutuximab β mainly included decreased hemoglobin，fever，vomiting，and diarrhea.The incidenceofadversereactionswashighestinthefirstcourseoftreatmentandthemediantimeofadversereactionsas2-5ays.Conclu sion：Targeted monitoring should be carried out at an early stage during dinutuximab β administration.Adverse reactions should be detected and managed earlyto ensure the safetyof medication forchildren.

【Key words】dinutuximab β ; neuroblastoma;adverse reaction

神经母细胞瘤（neuroblastoma，NB）是儿童最常见的颅外实体肿瘤，发病率约占儿童肿瘤性疾病的8%～10% ，病死率约占儿童肿瘤相关性死亡的 12% 215%[1] 。（剩余9490字）